
Commentary|Videos|June 14, 2025
Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL
Fact checked by: Ashling Wahner , Chris Ryan
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.
Advertisement
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed safety and efficacy findings from a phase 1b trial (NCT05421663) investigating the CD19/CD20–directed bispecific CAR T-cell therapy JNJ-90014496 in patients with relapsed/refractory large B-cell lymphoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5



































